Session – Lentiviral Vector GMP manufacture: Achieving Lower COGS and Shorter Time to Clinic Andy Lewin is Vice President, Business Development, with responsibility for the commercial leadership of the lentiviral vector manufacturing business at Oxford Biomedica. Andy joined OXB from AGC Biologics, where he was VP Business Development. Prior to that Andy served as Head of BD at Cobra Biologics, Head of BD and Project Management at SynCo BioPartners (now Wacker Biotech BV) and co-founder and Head of BD at BioOutsource (now Sartorius). Andy holds an MA in Biochemistry from the University of Oxford.